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Background: To compare retinal vascular measurements, biomarkers of cerebral small vessel disease (SVD), in HIV positive men aged 50 years and above with similarly-aged HIV negative men and younger HIV positive men. 
Methods: We recruited white, non-diabetic men to a cross-sectional substudy of a larger cohort including three demographically-matched groups. Optic disc centred 45° colour fundus photographs were used to calculate central retinal arterial and venous calibre and the arterial-venous ratio (AVR). We used univariate and multivariable linear regression to compare retinal vessel measurements in the three groups and to identify factors associated with AVR. 
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Conclusion: There were no differences in retinal vascular indices between HIV positive men aged >50 years and HIV negative men aged >50 years or HIV positive men aged <50 years, suggesting that HIV is not associated with an increased burden of cerebral SVD. 
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Study population We conducted a cross-sectional ophthalmic substudy within the Pharmacokinetic and Clinical Observations in People over Fifty (POPPY) study, a multicentre UK and Ireland cohort study exploring a range of age-associated measures of health, service use and pharmacokinetic parameters in PLWH (ClinicalTrials.gov Identifier: NCT01737047). POPPY comprises three demographically matched groups (PLWH aged >50 years; PLWH aged <50 years; HIV negative persons aged >50 years) in a 2:1:1 ratio and includes both white and black African participants. White, male, non-diabetic participants were recruited between May 2014 and July 2016 in London and Brighton, UK, in the same proportions as the parent cohort. Participants gave written, informed consent and the study was approved by the National Research Ethics Service Committee London – Camden & Islington, reference 14/LO/0316.   Sample size calculations were based on observations from a previous study,28 where the arteriolar diameter in participants over 50 was mean 159.13, standard deviation (SD) 17.63 in PLWH and mean 166.24, SD 18.56 in HIV negative participants. Assuming that similar differences existed in the target population, and maintaining the 2:1:1 ratio, we aimed to include 156 HIV positive men aged ≥50 years and 78 in each of the other two groups. This would achieve 80% power and an alpha level of 5% (STATA Statistics and Data Analysis software version 14.1, StataCorp, Texas, USA).   
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 calculation of CRAE and central retinal vein equivalent (CRVE) and the arterial-venous ratio (AVR) have been reported previously.30, 31 Diameters of all vessels crossing a zone 0.5 to 1 disc diameter from the disc margin were assessed by the same certified and validated grader with image analysis software. The calibres of the six largest arterioles and the six largest venules were combined to estimate the calibre of the central retinal artery and vein. The AVR, a ratio of these two measures, was calculated for each eye.  The POPPY cohort database provided clinical information relating to previous cardiovascular disease and risk factors, current and previous antiretroviral therapy use, latest CD4+ and CD8+ lymphocyte counts, anthropometric data, syphilis and hepatitis C virus serology, recreational drug use and serum lipids. Framingham 10-year cardiovascular disease risk was calculated using the framingham STATA module.32, 33  
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 drug class did not differ between the older and younger groups (total number on nucleoside reverse transcriptase inhibitors, 138 [86.8%]; non-nucleoside reverse transcriptase inhibitors, 82 [51.6%]; protease inhibitors, 76 [47.8%]; integrase inhibitors, 14 [8.8%]).  Prior ocular conditions in the final sample included cytomegalovirus retinitis (n=1), acanthamoeba infection resulting in a prosthesis on that side (n=1), hyaline asteroidosis (n=1) and cataracts (n=2), all of which were in PLWH aged ≥50 years. An additional 17 patients (8.1%) with drusen were identified (11 PLWH aged ≥50 years, 1 PLWH aged <50 years, and 5 HIV negative aged ≥50 years).  





Copyright ! 2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
9 
 95% CI -0.095 to 0.01, p=0.11) and a history of syphilis (β -0.015, 95% CI -0.034 to 0.005, p=0.14).   A multivariable model incorporating these variables, as well as study group, was then analysed (Fig. 2, solid lines). Systolic BP was included but diastolic BP was omitted because of collinearity (systolic BP had the stronger association of the two variables). Neither comparison group was associated with AVR when compared to HIV positive men aged >50 years (adjusted β 0.010 for HIV positive men <50 years, 95% CI -0.018 to 0.038, p=0.47; adjusted β 2.0×10-5 for HIV negative men >50 years, 95% CI -0.022 to 0.022, p=0.99). Factors associated with lower AVR in the multivariable model were systolic BP (adjusted β -0.009 per +10 mmHg, 95% CI -0.015 to -0.003, p=0.002), history of stroke or TIA (adjusted β -0.070, 95% CI -0.12 to -0.015, p=0.01), and recent recreational drug use (adjusted β -0.037, 95% CI -0.057 to -0.018, p=0.0002). Similar analyses (not shown) failed to show any association between the three study groups and either CRAE or CRVE. 
 















 In this study of 159 HIV positive and 52 HIV negative men, we found no association between HIV status and retinal vascular measurements. This is in keeping with the findings of a similar study in a South African population.28 As expected, we found associations with hypertension and stroke history, as well as an association with recent recreational drug use. Within the group of PLWH, there was a smaller AVR in those with higher absolute CD4+ lymphocyte count which may indicate the influence of immune activation, although CD4+:CD8+ cell ratio was not associated. We did not observe any association between the duration of antiretroviral therapy and retinal arteriolar narrowing 28, although this was observed in the South African study. PLWH receiving ART in South Africa differ markedly in their clinical features from the UK HIV positive population, and the healthcare systems providing HIV care have evolved in different ways, so there are several plausible explanations for the differences in our observations, including possible collinearity between age and duration of treatment in the South African patient sample.  Retinal photography with measurement of vascular calibre is widely used in epidemiological studies and clinical monitoring. Abnormal retinal diameters and qualitative features of retinopathy are associated with an increased risk of numerous conditions in middle-aged or older HIV negative people, including neuroimaging features of SVD, cognitive impairment, stroke, cardiovascular disease, incident diabetes, metabolic syndrome and all-cause mortality.23-
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Figure 1. Retinal vascular indices, showing mean and standard error for all three groups. 
 Footnotes: PLWH aged 50 years and above, squares (n=120); PLWH under 50 years, triangles (n=39); HIV negative aged 50 years and above, circles (n=52). Lower values of AVR and CRAE, and higher values of CRVE, are considered to be pathological. 










Figure 2. Factors associated with arterial-venous ratio, showing unadjusted (broken lines) and 
adjusted (solid lines) coefficients. 
 Footnotes: Multivariable estimates and 95% confidence intervals are shown. Leftward deflections in coefficient (negative values) indicate an association with lower AVR and more pathological change. Variables that were assessed in unadjusted models but are not shown here because p>0.2 were body mass index, waist circumference, lipids, smoking status, self-report of previous ischaemic heart disease, lifetime history of injection drug use and hepatitis C antibody status. AVR, arterial-venous ratio; BP, systolic blood pressure; PLWH, people living with HIV; TIA, transient ischaemic attack. 
 
 
Figure 3. HIV-related factors associated with arterial-venous ratio, showing partially adjusted 
(broken lines) and fully adjusted (solid lines) coefficients 
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value *   Age, median years (IQR) 59 (54, 65) 44 (41, 48) 60 (55, 65) 0.48 * Body mass index, median kg/m2 (IQR) 25.1 (23.5, 28.0) 23.8 (22.9, 27.4) 26.1 (23.6, 29.3) 0.08 Waist circumference, median cm (IQR) 93 (87, 99) 89 (85, 93) 93 (87, 102) 0.09 Blood pressure, median mmHg (IQR) Systolic Diastolic 
  127 (118, 139) 79 (72, 85) 
  124 (114, 132) 78 (71, 84) 
  129 (116, 140) 80 (72, 85) 
  0.21 0.62 Smoking, n (%) Current smoker Ever smoked 
 22 (18.3) 64 (53.3) 
 13 (33.3) 27 (69.2) 
 8 (15.4) 33 (63.5) 
 0.08 0.16 Recreational drug use in past 6 months, n (%) † 37 (30.8) 15 (38.5) 15 (28.8) 0.59 Ever injected drugs, n (%) 14 (11.7) 11 (28.2) 3 (5.8) 0.01 Framingham 10-year cardiovascular risk, median % (IQR) ‡ 
7.3 (5.3, 9.6) 2.8 (2.1, 4.2) 7.6 (5.9, 13.7) 0.22 * 
Medical history, n (%)  IHD Stroke or TIA Syphilis 
 17 (14.2) 7 (5.8) 53 (44.2) 
 1 (2.6) 0 11 (28.2) 
 5 (9.6) 0 10 (19.2) 
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Hepatitis C virus 13 (10.8) 3 (7.7) 0 0.03 Lipids, median mmol/L (IQR) ‡ Total cholesterol HDL LDL 
  5.0 (4.4, 5.6) 1.3 (1.0, 1.6) 2.8 (2.3, 3.5) 
  5.1 (4.6, 5.7) 1.3 (1.1, 1.6) 2.9 (2.4, 3.3) 
  5.0 (4.3, 5.8) 1.3 (1.0, 1.6) 3.0 (2.3, 3.5) 
  0.73 0.92 0.78 Years from HIV diagnosis to starting ART, median (IQR) 
3.0 (1.6, 7.0) 3.8 (2.2, 5.9) N/A 0.71 
Duration of ART, median years (IQR) 13.1 (6.8, 17.6) 6.8 (5.1, 11.5) N/A 0.0009 Lymphocytes  CD4+, median cells/μL (IQR) CD4+, median % (IQR) CD8+, median cells/μL (IQR) CD4+/CD8+ ratio 
 600 (470, 750)  31 (24, 37) 1015(745,1350)  0.69 (0.42,0.85) 
 740 (490, 930)  33.5 (28, 40) 745 (600, 1015)  0.87 (0.59,1.18) 
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